No patients had local anesthesia, to avoid volume distortion of tissues. Instead, the area to be injected was cooled with ice packs for two minutes. The skin was prepared by cleaning with 70% isopropyl alcohol (Sterets) wipes. Patients were seated upright, with their head against a headrest. Injections were administered with the physician on the ipsilateral side to be treated, with the standard 27-gauge needle supplied and the product on a Luer-Lok vial. The superficial temporal artery and obvious veins were identified to avoid needle entry. The skin over the temple was gently stretched perpendicular to the needle shaft, which was then inserted transcutaneously, bevel down, and advanced to a deep plane within the superficial temporal fascia. Filler was injected as the needle was slowly advanced. Each injection was layered, with up to 0.5 mL placed along the anterior temple just behind the frontozygomatic arch. The aim was to soften the sharp demarcation from the prominent bony arch to the volumedeficient soft tissue of the temple. The filler was then molded and massaged with the thumb and index finger to achieve the desired contour and reduce any prominent lumps, with approximately two to three injections per side.
Patients were advised to avoid exercise and alcohol for 24 hours and to avoid direct pressure on the temple for 72 hours. Regular ice packs and analgesia were recommended. All patients were contacted the day after treatment for telephone review, with immediate follow-up arranged if concerns emerged. Patient satisfaction and any complications were recorded at two weeks; after four to 14 (mean, nine) months, a satisfaction feedback questionnaire was mailed. Patients were asked about the presence and duration of lumpiness, discoloration, redness, swelling or bruising, the need for any touch-up treatments or dissolution of filler, and how long they felt the filler had lasted. In addition, two independent physicians assessed before and after photographs ( Figure 1 ) at four to 14 months following treatment and assigned a grade from 1 to 3, defined as follows: grade 1 (worse) showed lumpy or irregular contours, discoloration, or exaggeration of bony outlines; grade 2 had no noticeable change from preinjection photographs; and grade 3 (noticeable improvement) demonstrated smooth contour, improved convexity, and restoration of brow volume (Table 1) .
Results
Between January 2008 and April 2009, a total of 20 patients (18 women and two men) with a mean age of 46 years (range, 20-60 years) had treatment to 39 temples, all for the first time. Indications for treatment included facial rejuvenation (18), hypothyroid temple hollowing (one), and orbitotemporal neurofibromatosis-related facial asymmetry (one). All patients received 0.3 to 1.0 mL (mean, 0.9 mL) of filler per temple, except the man with asymmetry, who received 3 mL to one side ( Table 1) .
The postal questionnaire was returned by 18 (90%) patients. The survey yielded information regarding satisfaction with treatment and problems experienced ( Table 2) . Not all returned surveys contained complete data.
Eight patients responded to the question about the first time they became aware of temple hollowing, with symptoms ranging for a duration of one to 10 years (mean, four years). Of the patients who responded to the question about anesthetic efficacy, all 13 commented that ice pack skin cooling provided adequate analgesia. Eleven of 16 patients described either minimal or no discomfort during or after the injection. Three reported pain that was moderate but short-lasting, and two experienced pain that was severe but short-lasting. Of these two, one also experienced posttreatmetnt transient pain when chewing food.
Sixteen patients described a moderate or marked improvement in their appearance. Six of those 16 felt the results had exceeded their expectations, five felt their expectations were matched, and five were unsure what to expect. In terms of satisfaction, 11 of 16 patients were either very or extremely satisfied, three reported mild or moderate satisfaction, and two were ambivalent. No patients were dissatisfied. Nine of 13 felt that their selfconfidence was improved, whereas four reported that their self-confidence was unchanged and had not been a problem before treatment. Of 15 patients who commented, 13 planned to return for touch-up treatment when the improvement diminished. Eleven of 14 patients said they would recommend temple filler to a friend, two felt uncomfortable discussing aesthetic treatment with friends, and one felt that recommendation was unjustified.
At two weeks following treatment, all patients were considered to be improved, although one patient had an additional 2 mL of Perlane injected into the right side to correct residual asymmetry. The amount was determined on the basis of the desired aesthetic outcome. In two patients, the volume was constrained partly by financial consideration. In both of these cases, 1 mL was injected to each temple, which was considered by the surgeon to be only a partial correction. However, both patients described high levels of satisfaction at follow-up. One of these patients was graded as showing no objective improvement (grade 2) in the photographs by both independent physicians, whereas the other was scored by both as showing improvement after treatment (grade 3). Their grades were judged from photographs taken at 11 and eight months after treatment, respectively. Both patients planned to have further treatment at a later stage if required.
In one patient, the benefit was reduced by her hairstyle, which partly covered the temple area. A second patient noticed increased prominence of a superficial vein after treatment, lasting two months. Of the two patients who did not return the questionnaire, both had undergone treatment as part of facial rejuvenation and remained pleased with their results after six months. They continued their care in our clinic, but declined an invitation to complete the questionnaire survey.
Grading of photographic results by two independent physicians at each patient's most recent follow-up produced agreement that 15 of 20 cases had improved in their appearance. Physician 1 judged there to be no perceived benefit compared to pretreatment photographs in only two patients (at 11 and 13 months after treatment, respectively), whereas physician 2 reported no improvement in five patients, with follow-up ranging from six to 13 months. In these cases, patients were at least moderately happy with their own perception of improvement and all planned to have repeat treatment if they begin to perceive 
disCussion
In the young face, the temple area is smooth and convex and rises flush to the frontozygomatic arch so that the anterior bony margin of the temple (including the outer edge of the superolateral orbital rim) is not visible. The eyebrow, consisting of the brow hair and its underlying soft tissue convexity, also makes an important aesthetic contribution to the periorbita and should be considered a continuum of the temple. Volume loss of the brow-temple complex with age creates an angulated vector, causing the tail of the brow to turn sharply in a posterior direction, partially concealing it from frontal view. The temple area flattens initially and then forms a soft concavity. This unmasks the rim of the lateral orbit, contributing to "skeletalization" of the face.
The margin of the temporal fossa also becomes more apparent, commencing at the tail of the eyebrow and extending as a curved line superomedially at first before turning superolaterally, when viewed frontally ( Figure  1A) . Comparison of the aging face to earlier photographs helps to illustrate clipping of the tail of the eyebrow in the frontal view, as volume deflation rotates the tail of the brow posteriorly into the cavity of the temple hollow.
Temple hollowing as a function of facial aging is not usually perceived directly by the patient, but may contribute to his or her general feeling of dissatisfaction with his or her changing facial appearance. In our group, six patients reported that the results exceeded their expectations, illustrating that the significance of temple hollowing was not recognized initially. In patients with HIV and antiretroviral-related lipoatrophy, hollowing has been recognized and treated with products such as poly-L-lactic acid for several years with high levels of patient satisfaction. Such filler has been measured to last for up to three years after a single treatment. 4, 6, 7 This group of patients experience exaggerated facial soft tissue atrophy and may experience more dramatic results and reduced stigmatization following facial filler treatment, including temple hollow rejuvenation. Unlike more delicate areas such as the tear trough, contour irregularities (bumps and ridges) do not appear to be a significant or prolonged problem when filling the temple. [8] [9] [10] The skin is reasonably thick and underlying fat and muscle provide depth to the fossa, partially allowing for concealment of lumpiness. None of our patients perceived surface irregularities beyond the first few days (Figure 2A-C) .
Regarding longevity within the temple, we suggest that most of the aesthetic benefit remains one year after treatment. This prolonged action and absence of migration relates to the high viscosity of Perlane and the relative immobility of skin and subcutaneous tissue in that area. Of four patients who were reviewed beyond 12 months, only one felt the need for retreatment, undergoing a further treatment with 1.0 mL to both sides. The remaining three patients plan to have treatment in the future, but only once the effect of the original treatment has diminished significantly. We note the excellent results achieved by Kornstein 11 for brow reconstruction and suggest that our temple filler procedure complements brow contouring by adding further support to the tail. 12 In reviewing our results and photographs, we have observed that the improvement in temple rejuvenation following filler injection cannot be fully appreciated on the basis of frontal photographs only. We suggest that this method of assessment underreports the success of outcomes. Ideally, oblique views with standardized lighting help to demonstrate the overall improvement in convex contours in this region. However, the often subtle threedimensional changes in contour are only fully appreciated in person.
NASHA is safe and effective as a soft tissue filler due to its lack of immunogenicity, [13] [14] [15] [16] its stabilizing and hydrating properties, and the ability for rapid reversal if required. 17 No patients in this series requested hyaluronidase.
Potential limitations include the fact that patients with longer hair that is worn forward over the temples may not notice any improvement in overall facial appearance and, in our study, reported lower levels of posttreatment satisfaction. Such patients may still gain significant benefit if they change their hairstyle frequently or if they are already dissatisfied with clipping of their lateral eyebrow in the frontal view. When treating temples, the practitioner should be aware of the presence of superficial veins, as injecting underneath these may increase their prominence temporarily (up to two months in one case in this study). Bruising and transient mild discomfort upon chewing are commonplace and most likely due to bruising of the temporalis muscle. Patients should be warned of this in advance.
ConClusions
We found patient satisfaction to be high with temple filling and no serious side effects were encountered. Initial results suggest that patients maintain at least some benefit at one year. Because the aging process changes soft tissues over time, the nonpermanence of such products is advantageous. In time, there is likely to be a demand for products with greater longevity that also maintain reversibility and malleability. We found Perlane to be well suited to accurate dose titration for achieving a pleasing result.
disclosures

